Sustained-release of levodopa: single dose study of a new formulation
Identifieur interne : 002134 ( Main/Exploration ); précédent : 002133; suivant : 002135Sustained-release of levodopa: single dose study of a new formulation
Auteurs : M. Gerlach [Allemagne] ; W. Kuhn ; Th. Müller ; P. Klotz ; H. PrzuntekSource :
- Journal of Neural Transmission [ 0300-9564 ] ; 1996-06-01.
Abstract
Summary: Motor fluctuations and dyskinesias in Parkinsonian patients may be at least partially due to fluctuations of levodopa plasma concentrations. Sustained-release (SR) formulations of levodopa may present a promising, effective solution of this problem. Therefore we performed a 4-fold, crossover double-blind trial with a new SR preparation, tested in healthy volunteers (Gerlach et al., 1988) before, in 12 Parkinsonian subjects. Two different dosages of the pure new levodopa SR-preparation, a composition of 70% SR and 30% levodopa immediate release (IR) and a conventional IR levodopa preparation were compared by their pharmacokinetic behaviour and their clinical effects. The relative bioavailability of levodopa in plasma was 69% for the combination of SR and IR levodopa release, for the pure SR formulations (100mg levodopa) 54% and (200 mg levodopa) 55%, compared to the 100% of the standard form of IR release of 100 mg levodopa. In contrast to the conventional IR formulation the pharmacokinetic behaviour of the SR preparations showed no initial sharp peak, but more continuous and longer maintaining plasma concentrations of levodopa. Due to the small numbers of cases and the missing homogenity of the selected patients no statistical significant differences between the four preparations regarding the clinical response were observed. But the described pharmacokinetic behaviour gives hope, that these newly developed SR-preparations may lead to progress in the treatment of Parkinson's disease (prolongation of dosage intervals, reduction of motor fluctuations).
Url:
DOI: 10.1007/BF01271231
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sustained-release of levodopa: single dose study of a new formulation</title><author><name sortKey="Gerlach, M" sort="Gerlach, M" uniqKey="Gerlach M" first="M." last="Gerlach">M. Gerlach</name></author><author><name sortKey="Kuhn, W" sort="Kuhn, W" uniqKey="Kuhn W" first="W." last="Kuhn">W. Kuhn</name></author><author><name sortKey="Muller, Th" sort="Muller, Th" uniqKey="Muller T" first="Th." last="Müller">Th. Müller</name></author><author><name sortKey="Klotz, P" sort="Klotz, P" uniqKey="Klotz P" first="P." last="Klotz">P. Klotz</name></author><author><name sortKey="Przuntek, H" sort="Przuntek, H" uniqKey="Przuntek H" first="H." last="Przuntek">H. Przuntek</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D8EA2B549FFC2A9C3FB429DACF1357BA7B14887F</idno><date when="1996" year="1996">1996</date><idno type="doi">10.1007/BF01271231</idno><idno type="url">https://api.istex.fr/document/D8EA2B549FFC2A9C3FB429DACF1357BA7B14887F/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000279</idno><idno type="wicri:Area/Main/Curation">000232</idno><idno type="wicri:Area/Main/Exploration">002134</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Sustained-release of levodopa: single dose study of a new formulation</title><author><name sortKey="Gerlach, M" sort="Gerlach, M" uniqKey="Gerlach M" first="M." last="Gerlach">M. Gerlach</name><affiliation><wicri:noCountry code="subField">Bochum</wicri:noCountry></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Psychiatry, Neurochemistry, University of Würzburg, Würzburg</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Basse-Franconie</region><settlement type="city">Wurtzbourg</settlement></placeName></affiliation></author><author><name sortKey="Kuhn, W" sort="Kuhn, W" uniqKey="Kuhn W" first="W." last="Kuhn">W. Kuhn</name><affiliation><wicri:noCountry code="subField">Bochum</wicri:noCountry></affiliation></author><author><name sortKey="Muller, Th" sort="Muller, Th" uniqKey="Muller T" first="Th." last="Müller">Th. Müller</name><affiliation><wicri:noCountry code="subField">Bochum</wicri:noCountry></affiliation></author><author><name sortKey="Klotz, P" sort="Klotz, P" uniqKey="Klotz P" first="P." last="Klotz">P. Klotz</name><affiliation><wicri:noCountry code="subField">Bochum</wicri:noCountry></affiliation></author><author><name sortKey="Przuntek, H" sort="Przuntek, H" uniqKey="Przuntek H" first="H." last="Przuntek">H. Przuntek</name><affiliation><wicri:noCountry code="subField">Bochum</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neural Transmission</title><title level="j" type="sub">Basic neurosciences and genetics, Parkinson's disease and allied conditions, Alzheimer's disease and related disorders, biological psychiatry</title><title level="j" type="abbrev">J. Neural Transmission</title><idno type="ISSN">0300-9564</idno><idno type="eISSN">1435-1463</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Vienna</pubPlace><date type="published" when="1996-06-01">1996-06-01</date><biblScope unit="volume">103</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="717">717</biblScope><biblScope unit="page" to="727">727</biblScope></imprint><idno type="ISSN">0300-9564</idno></series><idno type="istex">D8EA2B549FFC2A9C3FB429DACF1357BA7B14887F</idno><idno type="DOI">10.1007/BF01271231</idno><idno type="ArticleID">Art7</idno><idno type="ArticleID">BF01271231</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0300-9564</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: Motor fluctuations and dyskinesias in Parkinsonian patients may be at least partially due to fluctuations of levodopa plasma concentrations. Sustained-release (SR) formulations of levodopa may present a promising, effective solution of this problem. Therefore we performed a 4-fold, crossover double-blind trial with a new SR preparation, tested in healthy volunteers (Gerlach et al., 1988) before, in 12 Parkinsonian subjects. Two different dosages of the pure new levodopa SR-preparation, a composition of 70% SR and 30% levodopa immediate release (IR) and a conventional IR levodopa preparation were compared by their pharmacokinetic behaviour and their clinical effects. The relative bioavailability of levodopa in plasma was 69% for the combination of SR and IR levodopa release, for the pure SR formulations (100mg levodopa) 54% and (200 mg levodopa) 55%, compared to the 100% of the standard form of IR release of 100 mg levodopa. In contrast to the conventional IR formulation the pharmacokinetic behaviour of the SR preparations showed no initial sharp peak, but more continuous and longer maintaining plasma concentrations of levodopa. Due to the small numbers of cases and the missing homogenity of the selected patients no statistical significant differences between the four preparations regarding the clinical response were observed. But the described pharmacokinetic behaviour gives hope, that these newly developed SR-preparations may lead to progress in the treatment of Parkinson's disease (prolongation of dosage intervals, reduction of motor fluctuations).</div></front></TEI><affiliations><list><country><li>Allemagne</li></country><region><li>Bavière</li><li>District de Basse-Franconie</li></region><settlement><li>Wurtzbourg</li></settlement></list><tree><noCountry><name sortKey="Klotz, P" sort="Klotz, P" uniqKey="Klotz P" first="P." last="Klotz">P. Klotz</name><name sortKey="Kuhn, W" sort="Kuhn, W" uniqKey="Kuhn W" first="W." last="Kuhn">W. Kuhn</name><name sortKey="Muller, Th" sort="Muller, Th" uniqKey="Muller T" first="Th." last="Müller">Th. Müller</name><name sortKey="Przuntek, H" sort="Przuntek, H" uniqKey="Przuntek H" first="H." last="Przuntek">H. Przuntek</name></noCountry><country name="Allemagne"><region name="Bavière"><name sortKey="Gerlach, M" sort="Gerlach, M" uniqKey="Gerlach M" first="M." last="Gerlach">M. Gerlach</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002134 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002134 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:D8EA2B549FFC2A9C3FB429DACF1357BA7B14887F
|texte= Sustained-release of levodopa: single dose study of a new formulation
}}
| This area was generated with Dilib version V0.6.23. |  |